Given the established roles of APRT in purine salvage pathways and LCAT in reverse cholesterol transport, future studies could prioritize developing targeted small-molecule therapeutics to modulate purine and cholesterol metabolic pathways, thereby intervening in COPD-associated metabolic reprogramming. Here, LCAT is linked to chronic obstructive pulmonary disease.